## SUPPLEMENTARY INFORMATION

## Meiosis I Progression in Spermatogenesis Requires a Type of Testis-specific 20S Core Proteasome

Qianting Zhang<sup>1</sup>, Shu-Yan Ji<sup>2</sup>, Kiran Busayavalasa<sup>1</sup>, Jingchen Shao<sup>1</sup>, Chao Yu<sup>1,#</sup>

## SUPPLEMENTARY FIGURES



Supplementary Fig. 1. Dynamics of protein ubiquitination (Ub) and  $\alpha$  subunits of proteasomes during spermatogenesis. a–b, Immunofluorescent staining of Ub (a) and  $\alpha$  subunits of 20S core proteasome ( $\alpha$  sub, b) in sections of PD42 testes. Different stages of seminiferous tubules are shown. The regions bordered with dashed lines are enlarged in the right. At least three testes were stained and analyzed. Scale bars, 25 µm.



Supplementary Fig. 2. Evolutionary scenery of *Psma7* and *Psma8*. a, Phylogenetic tree showing the evolutional relevance of PSMA7 and PSMA8 from different species. The protein sequences were downloaded from NCBI. The evolutionary history was inferred using the Neighbor-Joining method. Scale bar, 0.05 million years. b–c, Schematic diagram showing the genome fragments containing *Psma7* and *Psma8* (b), and the exon structures of *Psma7* and *Psma8* (c) in mouse. d, Schematic diagram showing the presence of PSMA7 and PSMA8 during evolution.



Supplementary Fig. 3. Expression of PSMA8 in mouse. a–b, Semi-quantitative PCR (a) and Western blotting (b) results showing specific expression of *Psma8* and *Psma7* in spermatocytes entering meiosis in testes. E16.5 ov, ovaries at embryonic day 16.5; PD, postnatal day; sgA, spermatogonia A; sgB, spermatogonia B; PreL, pre-leptonema; L-Z, leptonema-zygonema; Pac, pachynema; RS, round spermatids; ES, elongated spermatids. c, Western blotting detected the endogenous and overexpressed PSMA7 and PSMA8. OE, over-expression; Endo, endogenous. d, Western blotting showing the expression of PSMA8 in *Spo11<sup>-/-</sup>* and *Dmc1<sup>-/-</sup>* testes at PD21. Arrowhead indicates the PSMA8 band.



**Supplementary Fig. 4. Generation of** *Psma8* **knockout mice. a,** Genotyping result for the WT (+) and null (–) alleles of *Psma8.* +/+, +/– and –/– represent Wild-type (WT), heterozygous and homozygous mice, respectively. Markers (Mk) of DNA were indicated. **b,** Body weights of WT and *Psma8*<sup>-/-</sup> mice at indicated ages. The numbers of mice analyzed (n) were indicated. Error bar indicated S.E.M. \* P<0.001 by two-tailed Student's *t* tests. n.s., not significant. **c,** Pups/litter and litter numbers analyzed for indicated breeding. \*, no pups or pregnancies were observed through a 3-month breeding. n > 6 for each breeding set. **d,** Numbers and percentages of *Psma8*<sup>+/-</sup> male to *Psma8*<sup>+/-</sup> female breeding, or *Psma8*<sup>+/-</sup> male to *Psma8*<sup>+/-</sup> female breeding, or *Psma8*<sup>+/-</sup> male to *Psma8*<sup>-/-</sup> female breeding. **e,** Immunofluorescent staining showing successful deletion of PSMA8 in spermatocytes at PD16 and PD21. Scale bar, 100 µm.



Supplementary Fig. 5. Effects of PSMA8 deletion on protein ubiquitination and protein degradation. a, Real-time PCR results showing the levels of indicated genes in WT and *Psma8*<sup>-/-</sup> testes at PD42. b, Western blotting showing the effects of MG132 on WT and *Psma8*<sup>-/-</sup> testes. Spermatocytes were treated with 50  $\mu$ M MG132 for 4 h before sample preparation for Western blotting. RAD51 band intensity is quantified from three different blottings and the average is shown underneath the blotting. c–d, Immunofluorescent staining of TEX11 (c) and SPATA22 (d) in testes sections derived from WT and *Psma8*<sup>-/-</sup> males at PD25. Scale bars, 50  $\mu$ m. e, Western blotting results showing the levels of indicated proteins in WT and *Psma8*<sup>-/-</sup> testes at the ages of PD16 and PD42. Quantification of the intensity of Western blotting bands is shown under each blotting.



**Supplementary Fig. 6. Meiotic prophase I was less affected by PSMA8 deletion. a,** Staining of H1t showing that PSMA8-null spermatocytes progressed into late-pachytene stage. Scale bar, 50 μm. **b,** Hematoxylin & eosin (H&E) staining of testes and epididymis derived from WT and *Psma8*<sup>-/-</sup> males. Magnified images of testes were shown in Figure 6a. Scale bars, 50 μm. **c–d,** 

Staining of cleaved caspase 3 (CC3) showing the massive apoptosis after PSMA8 deletion (c), and the quantification of tubules containing massive CC3 signal was shown in (d). Scale bar, 50  $\mu$ m. Error bars indicated S.E.M. The numbers (n) of sections quantified are indicated. e, Staining of CDK1 phosphorylated at threonine 161 (pT161-CDK1) showing activation of CDK1 in indicated testes sections at PD25. Scale bar, 50  $\mu$ m.



Supplementary Fig. 7. RAD51 and RPA1 remained stable in WT and *Psma8*<sup>-/-</sup> oocytes. a–b, Immunostaining of RAD51 (a) and RPA1 (b) on WT and *Psma8*<sup>-/-</sup> ovary sections at PD1. Scale bars, 25  $\mu$ m.



Supplementary Fig. 8. Uncropped images of Western blotting results.

## Supplementary Table 1. Primer sequences.

Primer	Genes	Application	$S_{0}$
name	targeted	Application	Sequences (5 -5 )
P1	Psma8	Genotyping	5'-AAGGTTCTCTTTGTCATACTTGTCC-3'
P2	- 5mm	(443bp for WT)	5'- CCTTTTAAACATAGATGACCCTTTG-3'
Р3	Psma8	Genotyping (with P1; 200bp for WT allele)	5'-TTTTTTTCTACCCCAAGCACAA-3'
P4		Genotyping	5'-ATTCGAGGAACTAATATAGCTTGG-3'
P5	Psma8	(400bp for null allele)	5'-ATGCAAAAACCCACACATGTATAC-3'
S522	Dmc1	Genotyping	5'-CCGGCCAGATTACATTTCTT-3'
S523		(233bp/147bp for	5'-AAAGGGACTGCTGAGGCATA-3'
S524		WT/null allele)	5'-GCCAGAGGCCACTTGTGTAG-3'
S519		Genotyping	5'-CTGCTCAGGGAGGAGAACAC-3'
S520	Spo11	(165bp/200bp for	5'-TCAGGACAGGGCATAGCAGT-3'
S521		WT/null allele)	5'-GCCAGAGGCCACTTGTGTAG-3'
S185	Demag	PT PCP (215bp)	5'-CGAGGAACTAATATAGTTGTGCTTG-3'
S186	I Smuo	KI-I CK (2150p)	5'-ATATACTCTACAGTGACGGGATCCT-3'
C017	Psma7	RT-PCR (217bp)	5'-CCAAGTCAGTGCGTGAATTTC-3'
C018			5'-TCTTTCTCCTTCTCAATTTCAGC-3'
C051	Rad51	RT-PCR (186bp)	5'-TTTGGTGTCGCAGTGGTAATC-3'
C052			5'-AAGACAGGGAGAGTCATAGATTTTG-3'
Z531 Z532	Gapdh	RT-PCR (181bp)	5'-ACACTGAGGACCAGGTTGTCTC-3'